Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case

Am J Transplant. 2019 Oct;19(10):2939-2943. doi: 10.1111/ajt.15377. Epub 2019 Apr 23.

Abstract

The gastrointestinal stromal tumor (GIST) is a digestive neoplasm of mesenchymal lineage. The treatment strategy for receptor tyrosine kinase-mutated GISTs is well defined. Wild-type GISTs (WT-GISTs) respond unsatisfactorily to specific kinase inhibitors. Moreover, evidence shows that repeat surgery has limited benefit. We report the case of a young female patient who was diagnosed with liver metastatic WT-GIST, after initial radical resection and adjuvant therapy with molecular targeted drugs. Due to the disease progression, a two-stage surgery was performed, with the removal of extrahepatic lesions followed by a total hepatectomy. The patient is disease-free after 4 years from liver transplantation (LT), performed under everolimus-based immunosuppression. The treatment of WT-GISTs remains a significant challenge due to the frequent resistance to tyrosine kinase inhibitors (TKIs). Liver transplantation might represent an effective treatment option for such disease.

Keywords: cancer/malignancy/neoplasia: metastatic disease; clinical research/practice; immunosuppressive regimens; liver disease: malignant; liver transplantation/hepatology; organ allocation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Neoplasms / therapy*
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / therapy*
  • Humans
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Liver Transplantation / methods*
  • Molecular Targeted Therapy
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Protein Kinase Inhibitors